Status:
COMPLETED
Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Mixed Hyperlipidemia
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
This is a 12-week clinical trial in participants with mixed hyperlipidemia to study the effects of MK-0524B on lipids.The primary hypothesis is that MK-0524B (dosed as MK-0524A coadministered with sim...
Eligibility Criteria
Inclusion
- Participant 18 to 80 years of age with Mixed Hyperlipidemia with LDL-C between 130 and 190 mg/dL and Triglycerides between 150 and 500 mg/dL
Exclusion
- Pregnant or lactating women, or women intending to become pregnant
- Diabetes mellitus that is poorly controlled, newly diagnosed, or taking new or recently adjusted antidiabetic therapy (with the exception of ± 10 units of insulin)
- Human immunodeficiency virus (HIV) positive
- Any of the following within the past 3 months: heart attack, stoke, heart bypass surgery, unstable angina, angioplasty
- Active or chronic liver disease
Key Trial Info
Start Date :
January 24 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 6 2010
Estimated Enrollment :
2340 Patients enrolled
Trial Details
Trial ID
NCT00289900
Start Date
January 24 2006
End Date
August 6 2010
Last Update
August 31 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.